Table 1.  Molecular targeted therapy, phase and state of trials.

Drugs in HCC treatment	Mechanism of action	Target	Phase	Trials (n)	State of trials
Multikinase inhibitors
Sorafenib	TKI	VEGFR-2/-3, PDGFR-β, Raf-1, B-Raf, Flt-3, c-KIT, RET	I, I–II, II, III, IV	65	Closed
Sunitinib	TKI	VEGFR-1/-2, PDGFR-α and -β, Flt-3, c-KIT, RET	II, III	6	Closed
Linifanib	TKI	VEGFR, PDGFR family	II, III	2	Ongoing
Cabozantinib	TKI	VEGFR2	I, II	2	Ongoing
MET inhibitors
Tivantinib	Inhibits growth, induces apoptosis in c-MET-positive HCC	c-MET/HGF	I, II	3	Ongoing
Cabozantinib	Inhibits growth, induces apoptosis in c-MET-positive HCC	c-MET	I, II	2	Ongoing
Antiangiogenic agents
Bevacizumab	MAB	VEGF	I, I–II, II	20	Closed
Brivanib	MAB	FGF, VEGF	I, II, III	6	Ongoing
Ramucirumab	MAB	VEGFR-2	III	1	Ongoing

HCC: Hepatocellular carcinoma; MAB: Monoclonal antibody; TKI: Tyrosine kinase inhibitor.